3
Announcements
Trials
Browse
Landscape
Status
No longer available
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
289
Observational
14
Expanded_access
2
Sponsor
Cancer Type
Dermatologic
2
Tumor-Agnostic
1
Thoracic
1
Conditions
Melanoma
2
Interventions
trametinib
3
dabrafenib
3
talimogene laherparepvec
2
pembrolizumab
2
Nivolumab
2
Ipilimumab
2
ulixertinib
1
tebentafusp
1
pegilodecakin
1
omaveloxolone
1
methyl 5-aminolevulinate
1
lifileucel
1
efineptakin alfa
1
cemiplimab
1
balstilimab
1
avelumab
1
aldesleukin
1
Rose Bengal
1
Melphalan
1
HhAntag691
1
Cyclophosphamide
1
Brentuximab Vedotin
1
AM0010
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Expanded_access
×
Nivolumab
×
Dermatologic
×
Clear all
NCT06590480
2025-12-18
RPL-EAP-001
Replimune, Inc.
No longer available
NCT02186249
2017-02-08
CheckMate218
Bristol-Myers Squibb
No longer available